New pill aimed at Hard-to-Treat lung cancer shows early promise
NCT ID NCT03808558
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial is testing an experimental drug called TVB-2640 in 18 people with a specific type of advanced lung cancer that has a KRAS mutation and has not responded to standard treatments. Participants take the drug as a pill once daily for 8 weeks. The study aims to see if the drug can control the cancer and to check its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TVB-2640 (a drug taken as a pill once daily)
What this could lead to
If it works, this could point toward a new treatment option for people with a specific type of lung cancer that has not responded to other therapies.
What could go wrong
This is a small, early-phase trial with only 18 participants, so results may not apply to everyone. The drug may not shrink tumors or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS GENE MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Cincinnati
Cincinnati, Ohio, 45267, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390-9179, United States